Humabs BioMed Seeking Clinical Development Partner For ‘Natural Selection’ MAbs
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis and MedImmune have over the past several months also started clinical studies of antibodies licensed from the Swiss biotech, which derives its products from patients with highly effective immune responses.